- The recently-constructed Shanghai Industrial Zone went into operation in Pudong at the beginning of June. The establishment of this zone will step up the transformation of the R&D achievement of bio-engineering medicine to industrialization and promote the development of the modern biotechnology industry in China.
The first batch of research institutes and their industrialized products are listed below: -------------------------------------------------------------------------- Shanghai Huaxin Bio High-Tech Co IL-2 and IFN alfa 2b Shanghai Lianhe Saier hGH Bio-Engineering Co Shanghai Shiye Bio-Tech Co rSK Shanghai Sanwei Bio-Tech Co G-CSF --------------------------------------------------------------------------
The first stage of the project will be completed by the year 1997, and the second stage by the year 2000. Sales are expected to be around $120 million by then.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze